Intensity-modulated beam radiothera py (IMRT) delivers a highly conformal, three-dimensional (3-D) distribution of radiati on doses that is not possible with conventional methods. When administered to patients with head and neck tumors, IMRT allows for the treatment of multiple targets with different doses, while simultaneo usly minimizing radiation to uninvolved critical structures such as the parotid glands, optic chias m, and mandible. With 3-D computerized dose optimizat ion, IMRT is a vast improvement over the customary trial-and-error method of treatment planning.
Introduction
Th e objec tive of radio thera py is to maximi ze the radiation dose to the tum or, while keepin g the do se to the surro unding normal struct ures below their toleran ce for tox icity . Th e toler ance of norm al tissue to radi ati on is the limiting factor in dose delivery. The treatment of neoplasms of the head and neck is particul arly illustra tive of this probl em . Because these neoplasms are frequently in close proximity to critical structures-such as the parotid glands, mandibl e, spinal cord, brain stem , and the eye -misapplied radioth erapy can res ult in significant morbidity.
In con vent ional radi oth erapy, sta nda rd treatm ent protoco ls have evo lve d for var ious disease sites based on clinica l ex perie nce, reproducibility, and durat ion of treatment. The radiatio n dose delivered to the tu mor and surro unding tissue ca n be mod ified by adj usting the fixed treatment field s, beam energies, the use of elec tro ns, the we ight of different beams, and the use of wedges, bolu ses, and tissue co mpensa tors.
Unfor tunate ly, the standard trea tme nt planning process 
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INTENSITY·MODULATED RADIOTHERAPY: FIRST RESULTS WITH THIS NEW TECHNOLOG Y ON NEOPL ASMS OF THE HEAD AND NEC K head and neck neoplasms who were treated with IMRT at the Methodist Hospital in Houston. Amo ng the inform ation in the char ts were data on the site of the neopl asm , histologic diagnosis , staging (w hen appro priate), differentia tion between primary and recurre nt disease and between curative and palli ative treatment , the patient ' s history of radiation therapy (including dose, fraction size , toxicit y du ring treatment , and late toxicit y), and the status of the patient at the last follow up. Th e degree of acute toxicit y was determined by Rad iation Th erap y Oncology Group (RTOG) Acute Morbidity Scores at six sites : mucous membrane ; skin ; larynx, pharyn x, and esophagus; salivary gland s; eyes; and ears.'? The chart s also contained treatment plan s and record s of the volume of each parotid gland (ipsilateral and contralateral to the primary target ) that rece ived radi ation doses of 1,000 cGy, 2,000 cGy, and 3,000 cGy ( figure 3 ). 
mm .
For treatm ent planning purpo ses, physicians obtained a high-
Procedure
Before patient s can undergo IMR T, they must be immobili zed . Next, they must undergo co mputed tomography (CT) so that the physician can identi fy relevant struc tures and plan treatm ent. Th en the physician must determine the optimum dose to the tumor and ass ign dose limitation s to critical normal structures.
In preparation for immobilization , patients were placed under ge neral ane sthesia. A neurosurgeon then placed screws in the vertex of the skull. A talon (dockin g dev ice) was attache d to the screws , co mpleting the im mo b ilizatio n a nd readying the patient for the planning CT and subsequent daily treatment s. Th e degree of rep roduci bility in positioning patients for later treatm ent s was exce lle nt : within I 
Materials and Methods

Patients
We retro spectively reviewed the charts of the first 28 patients-24 males and 4 females, aged 10 to 92-with is based on trial and error, and modification of a spec ific treatmen t plan can requ ire hour s of computatio n without any guarantee that the result ant plan will be satisfac tory. Furth ermore, con ventional radiotherapy utilizes a relative ly small numb er of fixe d fields to deli ver a hom ogenous radiation dose to the tum or and surro unding structures. Wh en radi ation directed to normal tissues exceeds the tissues' tolerance, complications may occ ur.
Intensity-modulated beam radiothera py (lMRT) is a new technology that is based on arc rotati on of the beam throu gh 270°(figure I) and a collimator that has 40 small field s mea suring I ern! (figure 2). During rotation , the configuration of the collimator can be adjusted every 5°, thereby allowing for the deliv ery of highly con form al doses to a tumor whil e sparing the adj acent normal structures.
IMRT offers seve ral adva ntages ove r co nventional radiotherapy: its abil ity to treat a target within a target, its ability to escalate the dose to the tumor while sparing critica l struc tures, its use of 3-D co mputers for optimized treatm ent plannin g, and its ability to re-trea t previously irrad iated patient s. Never before has the radia tion onco logist been able to write a dose prescription for the avoidance of norm al tissue to such a degree.
After a thorou gh eva luation of the system, IMRT was first used clinica lly in the Unit ed States on March 2 1, 1994, at the Baylor College of Medicine in Houston .':" Th is article is a report of that series of procedures. In cases of tongue cancer , the tongu e was immobi lized with a stent that was specifically tailored to the patient' s anatomy. Glottic lesions were treated with slightly larg er fie lds to compensate for potential movement during therapy .
After the target and normal structures were identified , the computerized treatment pla nning system performed "inverse planni ng" and calculated optimal doses . (Planning is called "inverse" becau se rath er than placing the radi ation field first and then lookin g at the dose distribution around the tumor and norm al structures, the IMRT system defines the tumor and normal structures and assigns optimum do ses first. Th en the computer sys tem Table 1 . Patients with a history of radiation therapy determines the best treatment field.) As part of inverse planning, doses of radia tion were assigned to the tumor and norm al structures , and the co mputer defined the pattern of deliv ery of these doses. Dose optimiza tio n was acco mplished by ass igning weighted values to the target(s) and their surro unding struc tures according to their relative imp ortance. (Ta rge ts are usually given priority over normal adja cent tissue s when weight s are ass igned, but not always. If, for exampl e, the optic chiasm is surrounded by the target tumor and the patient ca nnot acce pt the risk of a loss of vision, the optic chi asm will be assign ed a higher weight.) Th e computer planning system then optimized the treatment plan by I ) minimizing the amo unt of radiation tha t was delivered to the surrounding structures, as ranked by their relative importance (weighted score) while 2) maximi zing the dose to the target(s).
Dose optimization was determined by calculating the "cost function ." In simplified term s, the cost funct ion is the sum of the amount of target structure that will be irradiated at less than the prescribed dose plu s the amount loss, decreased pup weightsand skel etal abnormal ities. No teratogenic or embryocidal enecishavebeen seen in ratswhen budesonide was admi nistered byinhalation at doses of 100-250 .ug/kg/day (600-1500 .ug/m'/day, approximately27-68 timesIhe humanrecommended starting dose based onl tg/kg/dayor 4-10times the human dosebased on/lg/m'/day). There are no adequate and well-controlled studies in pregnanl women. Budesonide should be used dur ing pregnancyonly if the potential benelit justifies thepot enti alrisk toIhefetus. Experiencewith oral glucocorticosteroids si nce their introduction in pharmacologic, as opposed tophysiologic. doses suggests that rodents are moreprone to teratogenic effects from glucocorticosteroids than humans. In addi tion, because there is a natural increase in gl ucocorlicosteroid production during pregnancy, most women will requi rea lower exogenous glucocorticosteroid dose and many will not need glucocorticosteroid treatment during pregnancy. I:ill= SYsllin:nervousness.
Musculoskel etal : myalgia, ar thral gi a. OVERDOSAGE Acute over dosagewi th Ihis dosage lorm is unlikely since onecanisterof Rhinocort Nasal tnhaleronly contains approximately 12.7 mg of budesonide. Chronicoverdosagemay resul t insigns/symptoms of hypercorticism (see WARNINGS andPRECAUTIONS). DOSAGE AND ADMINISTRATION Adultsandchi ldren6year s01ageand ol der:Therecommended startingdose is256 /lg daily, gi ven as ei ther two sprays ineachnostril morningandeveningor asloursprays ineach nostril inthe morning. Adecrease insymptoms mayoccur as soon as 24 hour salter onset of treatmenl wi thRhinocorl Nasat lnhaler bul generally it takes 3-7 daysto reach maximum benefit. Ifnoimprovement has beenobtainedbythe thirdweek ot treatmentwithRhinocort Nasal Inhaler, treatment should be discontinued. Alter thedesiredclini cal effecl hasbeen obtained,themaintenance dose should be reducedtothesmallest amount necessary for controlotsymptoms. II glucocorticosteroids aredi sconti nuedwhentheyst ill are needed, symptoms may not recur lorseveral days. Atrecommendeddoses, Rhinocort's therapeutic effects are localized tothe nose, therefore, concomitant treatment may be necessarytocounteract allergic eyesymptoms. Doses exceeding 256 Ji g daily (4 sprays/nostril) are not recom mended . Rh inocort Nasal Inhaler is not recommendedforchildrenbel ow 6yearsof ageorforchildren withnonallerpic per ennial rhini tisbecauseadequate numbers01these chil dren havenot been st udi ed. Directions for Use: Illustrated Patient's Instructions for Use accompany each packageof Rhinocort Nasal Inhaler. HOW SUPPLIED Rhinocort Nasal Inhaler issuppliec ina7.0gcani stercontaining200 metered dosesprovided wi thametering valve and nasal adapter together wi th Patient'sInstructions for Use. Each actuation detivers approximately 32/lg 01 micronized budesonidefromthe nasal adapter tothepatient. Caution: Federal (USA) law prohibitsdi spensingwi thout prescription. Rhinocort Nasal Inhaler should be st ored between 15' C(59' F)and 30'C (86' F)withIhe valveup. Shake well before use. Each inhal er with actuator is packaged in an aluminum foil pouch to protect the product from moist ure. Alter opening thealuminumpouch, theproductshouldbe usedwithi n6monthsand storage inanarea 01high humi dit y shouldbe avoided. Contents under pressure, 00 not puncture. 00 not use or storenear heat or open flame. Exposure to temperatures above 50'C (120' F)may cause thecanist er toexplode. Never throw thecontai ner into fire or an incinerator. Keep out otreachof children. Nate: The indented statement below is required bythe Federal government's Ctean Air Act for all products containi ngor manufacturedwi thcoloronuorocartons(CFCs).
WARNING: Containstrich loromonof luoromeihane. dichlorotetrauuoroetnane. and dichlorodi fluoromethane, substances which harm public health and environment by destroying ozone in the upper atmosphere. Anot ice similartotheabove WARNING hasbeenplaced inthe patient informat ionleallet01thisproduct pursuant toEPAregulations.
BRIEF SUMMARY OF PRESCRIBING INFORMATION
RHINOCORi (budesonide) Nasal lnhaler
For Intranasal UseOnly. Shake Wel l BeforeUse.
INDICATIONSAND USAGE Rhinocort Nasal Inhaler isindicatedforthe management ofsymptoms 01 seasonal or perennialallergic rhi niti sin adultsandchildren and nonallergicperennial rhinitisinadults. Rhinocort Nasal Inhaler is not recommended for treatment 01 nonallergic rhi nitis in chi tdren because adequate numbersofsuchchildren have not beenstudied. CONTRAINDICATIONS Hypersensitivitytoany 01 theingredientsofthispreparation contraindicates ilsuse. WARNINGS Thereplacement ofasystemic gl ucocorticosteroid withatopical glucocorticosteroidcanbe accompanied bysigns ofadrenalinsufficiency, and inadditionsome patientsmayexperience symptomsotwithdrawal, e.g., jointand/or muscular pain, lassitude and depression. Patients previously treat ed for prolonged periods with systemic gl ucocorticosteroi dsandtransferred totopical glucocorticosteroidsshouldbe car elullymonitoredforacute adrenal insuffi ciencyinresponsetostress. Inthose patientswho have asthma orother clinicatconditionsrequiringlong-term systemic glucocorticosteroidtreatment, too rapid adecreaseinsystemic glucocorticosteroidsmay cause asever e exacerbationof theirsymptoms. The use of Rhinocorl Nasal Inhaler withalternate-day systemic predn isone could increase the likelihood of hypothalamic-pituitary-adrenal (HPA) suppression compare d with a therap eutic dose 01eit her one alone. Therefore, Rhinocort Nasal Inhaler should be used with caution in patients already recei vi ng alternate-day prednisone treatment foranydisease. Inaddition, theconcomitantuse 01Rhinocort Nasal Inhalerwithother inhated gl ucocorticosteroidscould increase Ihe risk of signsorsympt oms of hypercortici smand/orsuppression of the HPA-axis. Patientswho are on drugs which suppress the immune systemare moresusceptibleto infections than healthy individuals. Chickenpox and measles,lor exampt e, canhaveamoreserious orevenfatal course innon-immune chitdren or adullson immunosuppressant dosesof corticosteroids. Insuch childrenor adulls, whohave not had these diseases, particular care shou ld be taken to avoid exposure. How the dose, rout e and durat ion 01 corticosteroi dadministration affects the riskof developing adisseminated infectionisnotkn own.The contribution ofthe underlying disease and/orpriorcorticost er oidtreatment tothe riskis also not known. IIexposed tochicken pox, prophylaxiswi thvaricella zoster immuneglobutin(VZIG) may be indicated. If exposed tomeasles, prophyl axis withpooled intramuscularimmunoglobulin(IG) may be indi cated. (See therespective packageinsert lorcomptete VZIG and IGprescribing infor mation). If chickenpox develops, treatment withantiviral agents may be consi dered. PRECAUTIONS General: Rarely, immediate hyper sensi tivit y reactio ns or con tact dermatitis may occur affer the intr anasal administration of budesonide. Rare instances of wheezing, nasal septum perforation and increased intraocul ar pressure havebeenreported followi ngthe intranasal appl ication 01 aerosolized glucocorticosteroi ds. Like other glucocorlicosteroids, budesonide is absorbed int o the circulation. Use of excessive doses of glucocorticosteroids may lead to signs or symptoms of hypercorlicism, suppression ofHPA lunction and/or suppression 01 growth inchild ren orteenagers. Insncn term stud ies oftheacute effect of inhaled budesonide 256 Ji g/dayon tower leggrowth (knemomet ry), it likeother inhaled and intramuscular corlicoids whichhave been studied showed adecrease inthe rate of lowerleggrowth. The clinical signi licance ofthisIindingisnot known. In two one-year studies in92 children faking recommended doses ofRhinocorlNasal Inhaler, height and skeletal staturewere consistent with chronological age. Physiciansshould closel y follow the growth 01children taking corticoids, byanyroute, and weigh thebenefitsof corticoidtherapy against Ihe possibil ilyof growthsuppression iI achild's growth appears slowed. Al though systemiceffects have been minimal withrecommended doses 01 Rhinocort Nasal Inhater , this potential risk increases withlarger doses. Therelore, larger thanrecom mended doses ofRhinocort Nasal Inhaler shouldbe avoided. When used at larger doses,systemic glucocorticosteroid elfectssuchas hypercorticism and adrenal suppression may appear. If such changes occur, the dosage of RhinocortNasal Inhaler should be disconti nued slowly, consistent with accepted procedures lor discontinuing oral gl ucocorticosleroidtherapy. Inclinical studies wilhbudesonide administered intranasally, the developmentof localized inl ectionsofthe nose and pharynx withCandida atbicans has occurred only rarety. When such an infection deve lops, it may requi re treatmentwith appropriate local therapy and disconlinuation oftreatment withRhinocort Nasat Inhaler. Patients using Rhinocorl Nasat Inhaler over several months or longer should be examined periodically for evidence 01 Candida infection orother signsofadverse effects onthenasal mucosa. Rhinocort Nasal Inhaler should be used withcaution, il atall, in patients withactive orquiescent tubercut ous infections, untreated lungal, bacterial, orsystemicviral inf ections, or ocul ar herpes simplex. 8ecauseofthe inhibitory effect of glucocor ticost eroi ds on wound healing, patients who have experienced recent nasal septalulcers, nasat surgery, or nasal trauma should not use a nasal gl ucocorticosteroiduntil healing has occurred. Information for Patients: Patientsbeing treated withRhi nocort Nasal Inhaler shouldreceive thelollowing inlormation and instruct ions. Patientsshoulduse Rhinocort Nasal Inhaleras prescribed. Adecrease insymptoms may occuras soon as 24hours alter starting gtucocorticosteroid therapy and generally can be expected tooccur within afew days ofiniliat ing therapy inallergicrhinitis. Thepatient shouldcontact the physician if symptoms donot improvebythree wee ks, oril the condilion worsens. Nasal irritation and/orburning aft eruseofthe spray occur onlyrarely withthi sproduct. Thepatient should contact the physician iI theyoccur repeated ly. Patients whoare oncorticosteroids should be warnedtoavoidexposuretochickenpox or measles. Patientsshould also be advised that il they are exposed, they should consult their physician without delay. Carcinogenesis, Mutagenesis, Impairm ent of Fertility: Long-term studies were conducted in mice and rats using oral administration to eva luate thecarci nogenicpotential 01budesonide. Therewas no evidence 01acarcinogenic effect when budesonide was administered orally for 91weeks tomice at doses up to200 Ji g/kg/day(600Ji g/m'/day). Ina104-week carcinogenicitystudy inSprague-Dawleyrats (41),astatisticallysignificant increase inthe inci dence 01gliomas was observed inmaleratsreceiving50Ji g/kg/day(300Ji g/m'/day) orally; no suchchangeswereseen inmalerats receiving doses 0110 and 25Ji g/kg/day(60 and 150 Jig/m' /day) or in lemateratsatany dose. Two additional 104-week carcinogenicitystudies havebeen perlormed withoral budesonide at doses 0150 Jig/kg/day (300 Jig/m'/day) inmale Sprague-Oawtey and Fischer rats.These studies didnotdemonstratean increasedglioma incidence in budesonide treated animats as compared withconcurrent controls orrelerence glucocorticosteroid treated groups (prednisolone and triamcinolone acetonide). Compared withconcurrentcont rol male Sprague-Dawley ratstherewas a statistically signilicantincrease in the incidence of hepatocellular tumors. This finding was confirmed in alt three steroid groups (budesonide, prednisolone, tri amci nol oneacetonide)inthesecond study inmal eSprague-Dawley rats. Themutagenicpotential ofbudesonide was evaluated insixdiffere nttest systems; Ames Salmonella/microsome plate test, mouse micronucfeustest, mouse lymphoma test. chromosome aberration test in human lymphocytes, sex-linked recess ive lethal lest inDrosophilamelanogaster, and DNA repa iranalysis inrat hepatocyteculture. No mutagenicor clastogenicproperties ofbudesonide werefound inany 01thetests. The ellect upon fertility and general reproducti ve per formance was studied in rats given bud esonide subcutaneously. At 20Ji g/kg/day (120,ug/m'/day) and higher dose levels, a decrease inmaternal body-weight gainwas observed along withadecrease inprenatal viabilityand vi abil ity01 theyoung at birthand duringlactation. No sucheffectswere noted at the dose level 5Ji9lkg/day(30Jig/m'/day). Pregnancy: Terat ogenic EIIects: Pregnancy Category C: As withother glucocorticoidsbudesonide has been shown tobe terat ogenicand ernbryocidal in rabbits and ratswhen given subcutaneously indoses exceeding 5 and 100 Ji g/kg/day (59 and 600 JiQ/m'/day), respectively. In these studies budesonide at 25 Ji g/kg/day (295Ji g/m'/day) given torabbitsand 500 Ji g/kg/day (3000 Ji g/m'/day) givento rats was foundto produce fetal Figure 3 . The percentage of the parotid volume and the amount of radiation delivered.
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Case 1
Benefi t: IMRT allows physicians to re-treat previously irradiated patie nts with minima l doses delivered to adjacent normal structures ( figure 4) .
A 67-year-old man with a history of a poorly differe ntiated T4NOMO nasopharyngeal carcinoma-with invasion into the middle cranial fossa in the area of the foramen ova le, the petrous apex , right cavernous sinus, and portions of the clivus-was first trea ted in 1994. His initial therapy consisted of one cycle of chemotherapy with 5-fluorouraci l and cisplatin (which had to be discontinued because of neurologic toxicity) and conventio nal radia tion therapy (6,700 cOy delivered to the area of primary disease and 6,000 cOy to the draining lyrnphat-
Case Studies
Four selected case studies illustrate some of the dist inct benefits (denoted by italics) that IMRT prov ides to the radiatio n oncologist:
Parotid doses were determined for both the contra latera l and ipsilateral glands in 12 patie nts. Paroti d glands that were in the target area were excl uded from the tissuesparing analysis . In patients who had midline tumors, the parotid doses were not typically identified during treatment planning and these, too, were not included in the analysis because they receive d minimal doses.
Altho ugh long-term outcome data have not yet matured, thus far only 1 of 20 (5%) definitively trea ted patien ts has demonstrated a local failure. 
Results
Twenty-eight patients with head or neck neoplasms were treated between March 1994 and April 1997. Patient characteristics and treatment details are shown in table 1 (for patients who had a history of radiotherapy) and table 2 (for patients who receive d primary therapy).
Acute toxici ty was graded accor ding to RTOO criteria, from grade 1 (mild) to grade 4 (severe), and found to be minimal for the ear, eye, salivary glands, and skin. In genera l, grade 3 (moderate) complications were confined to patients who were treated with a full dose that covered a large volume of mucosal membrane within the oral cavity and oropharynx in an accelerated fractionation scheme. (Full doses were adminis tered to 18 patie nts who had had no previous radiotherapy.) These complicatio ns were clea rly the result of the aggressive treatment and were no differen t from those seen after acce lerated treatment with standard techniques. Two patients required feeding tubes due to poor ora l intake that was related to mucositis. Otherwise, treatment was extreme ly well tolera ted. The skull screws were well tolerated by all but 1 patient, who experienced a wound infec tion at his screw site. , Analysis of the dose delivered to the parotid glands revealed an excep tional degree of tissue spar ing, as significant portions of these glands received doses that are considere d to be within their tolerance limit ( figure 3) .
of normal structure that will be irradiated at more than the limiting dose, weighted by their assigned priori ty. The objective is to minim ize the cost function.
Dose modulation was accomplished with the special dynamic computer -controlled multivane collimator ( figure 2) . The apertures of the 40 small "beams" on the collimator are calibrate d in increments of 10% at every 5°of arc, as determined by intensity distribution patterns generated by the computer program.
After the planning was completed, extensive quality assurance with film dosimetry was performed to document dosimetry. Therapy was then initiated. The daily setup time was typically 5 to 10 minutes, and the duration of treatment ranged from 12 to 15 miriutes for patients who receive d two or three arcs, up to as long as 30 minutes for eight arcs . 
Case 2
Benefit : IMRTcan be used to trace nerves to the base ofthe skull while minim izing the radiation dose to the parotid glands and other surrounding structures. Different doses can be delivered to the primm}' site and to the nerve path ( figure 5) .
A 50-year-old man had a 4-year history of palatal discomfort. An exc isional biop sy of the soft palate lesion revealed a well-differentiat ed adenoid cystic carcinoma of the cribri form type. The tumor ex hibited perin eural inva sion. CT ex amination of the pharynx and skull base reveal ed no evidence of disease in the pterygopalatine fossa or in the foramen rotundum. The patient was referred for evaluation by radiotherapy, and he elected to undergo IMRT.
The patient recei ved 6,000 cGy (in 25 fractions of 240 cGy eac h) at the prima ry site and another 5,000 cGy (25 fractions of 200 cGy) extending along the nerve pathw ay at risk back to Meckel' s cave. Minimal doses were deli vered to the critical structures : the mandibl e ( 1,413 cGy ), lenses (650 cGy) , optic chiasm (176 cGy), optic nerves ( 1,202 cGy), retina (677 cGy), brainstem (1,246 cGy), spinal cord ( 1,195 cGy), right parotid ( 1, 186 cGy), and left parotid (1,534 cGy) . The patient tole rated IMRT well, although durin g treatm ent he developed moderate mucositis (RTOG grade 3), mild xerostomia (grade I), and mild dysphagia (grade 1). At 14 month s post-therapy, he had no ev idence of disea se or late complications of radiotherapy. ics). Radiation co mplica tions included xerostomia, retin al neovasc ularization, and skin changes on the neck. An MRI performed in Decemb er 1995 showe d that his disease had progressed to the point tha t he was no longer co nsidere d to be a goo d ca ndidate for co nve ntional radiation, and he was still not a good candidate for chemotherapy. He was referred for IMRT.
The man recei ved 4,000 cGy (in 20 fractions of 200 cGy each ) at the prim ary site. Radiation doses were minimized at the critical structures that were identified durin g treatment planning: the temporal lobes of the brain ( 1,320 cGy ), the lens of each eye (273 cG y), the orbits (250 cG y, 327 cGy), the optic chiasm ( 172 cGy ), the brainstem (509 cGy), and the optic nerves (3 11 cGy) . The patient tolerated IMRT extremely well and manifested no evidence of acute toxicit y. Figure 6 . The treatment planning screen for case 3. With the SMART boost technique , different doses can be delivered to the primary tumor and to the neck simultaneously. This allows for once-a-day radiotherapy that can be completed in a shorter amount of time.
(54 1 cOy ), brain (388 cOy), brai nstem ( 1,4 18 cOy ), and spinal cord (895 cOy). The patient tolerated radiation extremely well, with no evidence of acute toxicity. After doses can be delivered simultaneo usly to a primal)' tumo r in the neck and to the rest of the neck itself, which makes possible once-a-day radiotherapy that can be completed in a shorter amount oftime (fig ure  6) .
A 62-year-old man had a 2-month history of a progressive sore throat on the left. On exa mination, he was noted to have a 4em ulcerative lesion of the soft palate and anterior tonsillar pillar. Incisional biopsy revealed a moderately differentiated squamous cell carcinoma. Based on the physical exam, CT, triple endosco py, and chest x-ray , the patient was staged as T3NOMO. After a multidisciplinary evaluation, he decid ed to undergo IMRT.
The patient recei ved 6,000 cOy (25 fractions of 240 cOy) at the primary site and 5,000 cOy (25 fractions of200 cOy) in the cer vical lymp hatics to control possib le microscopic disease. Again, doses were minimized at the critica l structures : spinal co rd ( 1,977 cOy) , brain stem (669 cO y), left paro tid gland· (2,277 cOy), right parotid gland (5,226 cOy), mand ible (3,587 cOy), and orbits (73 cOy) . The patient compl eted his radiation as scheduled, but he developed conflu ent mucositis (RTOO stage 3) and experienced a weight loss of 15 Ibs dur ing treatment, which necessitated the placement of a feeding tube.
Case 4
Benefit: Multiple targets can be treated while minimizing doses to adjacent normal structures ( figure 7) .
A 72-year-old man gave a history of a left-sided glomusju gulare, which extended from the base of his skull to the internal auditory canal and which involved thej ugular foramen, caro tid canal, and hypoglossal canal. The co ndition resulted in deficits of cranial nerves VIII through XII. An MR I to evaluate the lesion showed the presence of a pituitary macroadenoma (2 x 1.5 x I ern). Multidisciplin ary evaluation revealed that the pituitary macro adenoma was nonsecretin g, and that both lesions would be treated by IMRT.
Th e patient received 4,500 cO y at the pitui tary ade noma and the glomus ju gulare (25 fractions of 180 cOy ). Doses were minimi zed at cri tical structures: optic chiasm (3,981 cOy), optic nerve ( 1,286 cOy), orbits boost," and the Continuous Hyperfractionated Acce lerated Radi oth erapy (C HA RT) .14One exceptio n to twice-aday frac tionation is the Po lish regim en , also ca lled Co ntinuous Accelerated Radi oth erapy (CA RE) , in which pati ent s are treat ed once a day eve ry day of the week, includi ng weekends." With our own SMART boost regimen , patients und ergo IMRT only once a day, but they still receive a higher-than-c on venti onal dose at the primary target (ie, a site of visible and/o r pa lpable disease) along with a co nve ntiona l frac tion at the secondary target (ie, a reg ion at risk fo r micro scopi c disease) . T his reg ime n is more convenie nt and is likely to be more cos t-effective th an tw ice-a-d ay dosing.
In co nventional radiotherapy, we frequently deal with whole-organ tolerance. Wh en only a porti on of an orga n is irradia ted, its tolerance is likely to increase. T hro ugh the accumulation of clinical and dose volume data regardin g new radi oth erapy technologies, we are likely to improve our understandin g of partial -organ tolerance and per haps significantly increase the radi ation dose to tum or s.
IMRT has made fea sible new approaches to radiotherap y in head and neck neopl asm s. Clinica l da ta are continuously bein g accumulated , and it is hop ed that they w ill dem on strate an imp ro vement in c ure rates and a redu cti on in morbidity.
MGH* accelerated sp lit co urse
Continuous twice-a-day Standard fract ionation Scheme the completion of ther apy, the pati ent 's ability to swa llow improved . An MRI 2 years after therapy revealed a dramatic shrinkage of the pituitary adenoma, but the glomus tumor rem ained unchanged .
Discussion
IMRT has four primary ad-MDACCt concomitant boost va ntages for the radiati on oncologist: con formal avoidance of normal tissue , computer-CHART § optimized treatment plann ing, CAREã reduction in the overall durat ion of treatment, and em-S MART" boost technique pha sis on partial-organ tolerance .
With co nventiona l technology, the radiati on onco logist's ability to avoid deposit ing full radiation doses in nearby normal tissues is limited. IMRT allows physician s to plan and deli ver se lective doses that conformally avoid norm al critical structures that either lie adjace nt to or are surrounded by the tumor. The four specific cases described her e illu strate thi s point w ith reference to the parotid gland. Conv entional radi otherap y technology freque ntly delivers larg e radia tion doses to most of the ent ire parotid glands, which oft en lead s to permanent xeros to mia and ad versely affect s the patient' s quality of life. The ability to spare the parotid s while depositing tumoricidal doses to the prim ary target lessens the severity of xerostomi a with out j eopardizing co ntro l of the tumor. The ab ility to conformally avoid normal structures makes dos e es calation to the tum or a mor e fea sibl e option.
With con ventional radiotherapy, planning treatm ent is an exe rcise in trial and error. It is also tim e con suming and does not alwa ys produce the best solutions. With IMRT, fast, power ful computer s ca n ide ntify and evaluate many "iterations" (combi nations of deli very inten sity) within a re ason abl e tim e and use math em atic al model s to find optimal solutions clo se st to the radiation oncologist ' s prescripti on .
IMRT' s ability to shorten the overall duration of treatment in head and neck ca ncer with its accelerated functional rad iation has improved local co ntro l by 15 %.11 -15 Th e biolo gic explanation is that IMRT inhibits tum or cell repopulation. Conventio nal acce lera ted radiatio n therapy has been typically adm inistered in more than one fraction per day . Some of the differen t schemata are listed in tabl e 3; they include the Ma ssachu sett s General Hosp ital accelerated sp lit course," the M.D . And er son co nco mitant 250
